Revolution Medicines, Inc. (RVMD) Misses Q3 EPS by 5c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q3 EPS of ($0.94), $0.05 worse than the analyst estimate of ($0.89). Revenue for the quarter came in at $0 versus the consensus estimate of $807.69 thousand.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Femasys Inc. (FEMY) Misses Q2 EPS by 20c